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Jan PruszakAbstract
For a range of nervous system disorders current treatment options remain limited. Focusing on Parkinson’s disease
as a neurodegenerative entity that affects an increasing quantity of people in our aging societies, we briefly discuss
remaining challenges and opportunities that neural stem cell therapy might be able to offer. Providing a snapshot
of neural transplantation paradigms, we contemplate possible imminent translational scenarios and discuss critical
requirements to be considered before clinical implementation.
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Repairing the central nervous system may appear daunting
in light of how little we still understand about its intricate
molecular and cellular structure. Nevertheless, concepts of
neural cell transplantation were explored early on, and
since the 1980s there have been more concentrated system-
atic efforts in the area of Parkinson’s disease, specifically,
which is used here as a salient example (for review, see [1])
(Figure 1). Its progressive, widespread pathology includes a
rather circumscribed epicenter of cell loss: the dopamin-
ergic neurons located in the ventral midbrain which send
axonal projections to target cells in the striatum and play a
critical role in the control of voluntary movement. Based
on a solid fundament of rodent and primate studies, func-
tional replacement of the dopaminergic neuronal subset by
engrafting fetal midbrain tissue has been unequivocally
demonstrated (for review, see [2,3]).Discussion
This body of work has led to clinical trials (for review and
meta-analysis, see [4]) including double blind, sham-
surgery controlled [5,6] and open-label studies with varying
clinical and neuropathological outcomes and assess-
ments [7-9]. The important proof-of-principle, however,
that neural cell preparations can survive long-term, re-
store function and alleviate neurological disease by means
of “replacement” was provided by these studies [10,11]. In
addition, cell preparations from various tissues of origin
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stated.including long term-expanded neural lines, hematopoietic
and other mesenchymal-derived sources. The associated
disease modulatory effects may carry the potential for med-
ical benefit, and non-neural cells could serve as vehicles for
trophic factor release or gene delivery but do not represent
cell replacement in the sense of the original ambitions. A
number of phase-1 clinical trials have been initiated based
on, at least partially, comparably limited sets of pre-clinical
data. When considering such paradigms, one critical de-
mand will be that the overall efficacy supersedes that of
current standard or alternative experimental therapeutic
options (even if the threshold to clinical translation appears
somewhat lower due to the perceived “safer” character of
such sources [12,13]). In addition to continuously improv-
ing pharmacological therapies (for review, see [14]), as well
as neurostimulatory approaches using electrode implant-
ation (deep brain stimulation) (for review, see [15]), RNA
interference-based approaches that aim for amelioration of
disease by preventing formation of the pathognomonic
neural protein aggregates, for instance, have to be consid-
ered as potentially feasible, promising therapeutic alterna-
tives (for review, see [16]). Still, the lasting structural and
functional repair of neural circuits by means of cell re-
placement is a worthy goal with potential biomedical
benefit beyond what experimental alternatives may offer
[17]. To achieve more reliable and predictable outcomes
post-transplantation of fetal ventral midbrain tissue for
Parkinson’s disease, an ongoing multicenter clinical pro-
gram aims at fine-tuning and coordinating neural trans-
plantation procedures and protocols [18]. Long-term it is
unlikely, as ethically problematic and technically hardly
feasible, to consider human fetal neural cell preparationsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Candidates for neural cell replacement therapy? A range of neurological disorders affecting the central as well as the peripheral
nervous system are being considered to be amenable to cell therapeutic intervention. These include defects associated with aging, injury and/or
genetic and developmental disorders. Neural cell sources to be administered include neural stem and precursor cells, astro- or oligodendroglial
preparations and postmitotic neurons.
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stones to achieve in bringing neural cell replacement to
the clinics? Among the most important requirements is
the generation of the actual therapeutic agent, i.e. the cell
preparation to be administered, and pluripotent sources
may provide a scalable and potentially efficacious alter-
native [19,20]. It will be critical to specify functional
equivalents of the phenotypes in need, and to exclude
uncontrolled generation of proliferative or otherwise un-
wanted subtypes [21,22]. On a cellular level, this requires
the reliable control of gene regulatory networks that de-
fine the phenotype of interest [23], on a biotechnological
level the development of reliable, scalable protocols that
predictably generate the desired cell type from pluripotent
or multipotent sources [24]. Learning from the ontogenic
neural stem cell niche, extracellular matrix molecules,
growth and patterning factors or small molecule inducers
can be applied to generate cells that approximate the
physiological equivalent in vitro (for review, see [25]). A cell
source to be applied in a therapeutic context requires an
explicit “score card” of characteristics that need to be met
(Figure 2), which may include expression of definitive gene
loci, transmitter release and electrophysiological activities
and surface molecular patterns. The first and the latter can
be economically and efficiently tested by implementing cus-
tomized arrays [26] and flow cytometric readouts [21,22]
into the cell production routines. Although the central ner-
vous system has been regarded as a somewhat immuneprivileged site [27], the immunogenic potential of the cell
preparation also needs to be considered [28]. Patient-
derived induced-pluripotent stem cell preparations pro-
vide options for autologous transplantation, but it remains
to be seen whether the complex methodological work-
flows (donor cell harvesting, reprogramming, expansion,
induction of phenotype, transplantation) could ever be
sufficiently economized to make this a clinical reality. Eas-
ier to envision is a cell bank with major histocompatibility
complex profiles that closely match particular patient sub-
sets [29]. Of equal significance to basic research and bio-
technological efforts is the parallel refinement of medical
parameters which include the identification of:
 The best candidate disease, the most appropriate
patient collective and disease stage to intervene,
taking into account the conditions of the host/
recipient tissue at the implantation site.
 The most appropriate means of delivery and
diagnostically conclusive readout assessments.
 The means to avoid potential unwanted side-effects
and to ensure proper access to follow-up and paral-
lel supportive therapies.
In a nascent journal on Molecular and Cellular Therap-
ies, one may explore opportunities for further innovative
developments. Induced pluripotent stem cell technology
[20] and direct phenotype conversion by epigenetic
Figure 2 Score card for cell preparations for clinical transplantation in Parkinson’s disease. Parameters listed here may serve to illustrate
criteria that would need to be met by a cell source before application as a therapeutic agent to treat neurological disease. (A) General features
refer to properties to be ensured in a range of pre-clinical, biotechnical studies regarding the cell source in question. This includes safety-related
(e.g., absence of tumor formation) and also efficacy-related issues such as phenotypic functionality (e.g., histological integration into the host
tissue and functional restoration of the neural circuitry). (B) Specific features refer to properties that would be considered as a means of quality
control of each batch or cell preparation in clinical-biotechnological routines as part of the actual clinical trial. Examples of intracellular or surface
markers that may be used to characterize (dopaminergic) neuronal cell preparations are given.
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with novel tools for genome editing of human cell lines (for
review, see [31]) make it conceivable that disease correction
of such autologous cell sources could efficiently be per-
formed before readministration to the patient. Epigenetic
(re)programming will require sophisticated insights into the
most appropriate gene expression make-up (dosage and
ratios) of the needed phenotype. Moreover, continuous
optimization of directed cell differentiation and recent de-
velopments in 3D differentiation systems that imitate em-
bryological tissue context may provide an avenue to yield
close-to physiological cell types [32]. In terms of delivery,
cell administration via the blood stream or cerebrospinal
fluid (intrathecally) may eventually complement the
current standard neuro-stereotactic approaches. Poten-
tially, one could exploit certain “cellular homing” behavior
to a lesion in certain contexts (tumors, inflammation, is-
chemia). For neurodevelopmental disorders, modes of de-
livery may include in utero surgery (for review of spina
bifida as a clinical example, see [33]). Finally, an attract-
ive option is to enhance the limited neuroregenerativecapacities of the brain itself for intrinsic cell replace-
ment (for review see [34]). As illustrated by the rapid
and unexpected developments in stem cell biology of
the past few years and months, predicting the actual
biomedical realities may be difficult. More important
may be postulating self-imposed, if not regulatory, cri-
teria that could guide future developments:
 To remain aware of the considerable responsibilities
that come with conducting work (funded) to
diminish human suffering caused by disease and the
concomitant hopes put into our daily work.
 To not compromise on the demand for functional
effects and to critically evaluate the need for animal
studies before clinical translation (behavioral recovery).
 To educate the public, including patients, caretakers
and family members as well as organizations (and
funding bodies) and moderate their enthusiasm, hope
and unjustified expectations, where appropriate.
 To remain cautious about too early clinical
translation and to take clear stands against clinical
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evidence (see [12,13]).
Adherence to such principles ensures lasting trust to-
ward this field and may avert unwarranted hype, while
maintaining the justifiable enthusiasm and motivation that
clinicians, physician-scientists and basic researchers work-
ing in the fields of regenerative medicine and applied stem
cell biology share in terms of bringing the joint scientific
efforts to clinical fruition.
Conclusion
As optimized protocols generate increasingly authentic
and safer neural cell preparations, future efforts may
focus on refining parameters of patient selection and cell
delivery. Ultimately, enhanced interdisciplinary dialogue
and applying the highest scientific standards on all levels
from basic stem cell biology to clinical protocol develop-
ment may make neural cell restoration via cell therapy a
clinical reality.
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